Table S3 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

Jiajun Zhang,Weihai Liu,Changye Zou,Zhiqiang Zhao,Yuanying Lai,Zhi Shi,Xianbiao Xie,Gang Huang,Yongqian Wang,Xuelin Zhang,Zepei Fan,Qiao Su,Junqiang Yin,Jingnan Shen

DOI: https://doi.org/10.1158/1078-0432.22474959.v1

2023-01-01

Abstract:Primers used in this study.

What problem does this paper attempt to address?

Table S1 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

Jiajun Zhang,Weihai Liu,Changye Zou,Zhiqiang Zhao,Yuanying Lai,Zhi Shi,Xianbiao Xie,Gang Huang,Yongqian Wang,Xuelin Zhang,Zepei Fan,Qiao Su,Junqiang Yin,Jingnan Shen

DOI: https://doi.org/10.1158/1078-0432.22474965

2023-01-01

Abstract:Super-enhancer analysis based on H3K27Ac ChIP-seq in U2-OS and SJSA-1 cells.
Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

Jiajun Zhang,Weihai Liu,Changye Zou,Zhiqiang Zhao,Yuanying Lai,Zhi Shi,Xianbiao Xie,Gang Huang,Yongqian Wang,Xuelin Zhang,Zepei Fan,Qiao Su,Junqiang Yin,Jingnan Shen

DOI: https://doi.org/10.1158/1078-0432.ccr-19-1418

IF: 13.801

2020-01-01

Clinical Cancer Research

Abstract:Malignancy of cancer cells depends on the active transcription of tumor-associated genes. Recently, unique clusters of transcriptional enhancers, termed super-enhancers, have been reported to drive the expression of genes that define cell identity. In this study, we characterized specific super-enhancer-associated genes of osteosarcoma, and explored their potential therapeutic value.Super-enhancer regions were characterized through chromatin immunoprecipitation sequencing (ChIP-seq). RT-qPCR was used to detect the mRNA level of CDK7 in patient specimens and confirm the regulation of sensitive oncogenes by THZ2. The phosphorylation of the initiation-associated sites of RNA polymerase II (RNAPII) C-terminal repeat domain (CTD) was measured using Western blotting. Microarray expression analysis was conducted to explore transcriptional changes after THZ2 treatment. A variety of in vitro and in vivo assays were performed to assess the effects of CDK7 knockdown and THZ2 treatment in osteosarcoma.Super-enhancers were associated with oncogenic transcripts and key genes encoding cell-type-specific transcription factors in osteosarcoma. Knockdown of transcription factor CDK7 reduced phosphorylation of the RNAPII CTD, and suppressed the growth and metastasis of osteosarcoma. A new specific CDK7 inhibitor, THZ2, suppressed cancer biology by inhibition of transcriptional activity. Compared with typical enhancers, osteosarcoma super-enhancer-associated oncogenes were particular vulnerable to this transcriptional disruption. THZ2 exhibited a powerful anti-osteosarcoma effect in vitro and in vivo.Super-enhancer-associated genes contribute to the malignant potential of osteosarcoma, and selectively targeting super-enhancer-associated oncogenes with the specific CDK7 inhibitor THZ2 might be a promising therapeutic strategy for patients with osteosarcoma.
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419828

2023-01-01

Abstract:Supplementary Table S2. Patient characteristics
Table S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419825.v1

2023-01-01

Abstract:Supplementary Table S3. Demographics of the included 332 osteosarcomas.
Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma

Demeng Chen,Zhiqiang Zhao,Zixin Huang,Du-Chu Chen,Xin-Xing Zhu,Yi-Ze Wang,Ya-Wei Yan,Shaojun Tang,Subha Madhavan,Weiyi Ni,Zhan-peng Huang,Wen Li,Weidong Ji,Huangxuan Shen,Shuibin Lin,Yi-Zhou Jiang

DOI: https://doi.org/10.1038/s41413-018-0009-8

IF: 12.7

2018-01-01

Bone Research

Abstract:Osteosarcoma is the most common primary bone sarcoma that mostly occurs in young adults. The causes of osteosarcoma are heterogeneous and still not fully understood. Identification of novel, important oncogenic factors in osteosarcoma and development of better, effective therapeutic approaches are in urgent need for better treatment of osteosarcoma patients. In this study, we uncovered that the oncogene MYC is significantly upregulated in metastastic osteosarcoma samples. In addition, high MYC expression is associated with poor survival of osteosarcoma patients. Analysis of MYC targets in osteosarcoma revealed that most of the osteosarcoma super enhancer genes are bound by MYC. Treatment of osteosarcoma cells with super enhancer inhibitors THZ1 and JQ1 effectively suppresses the proliferation, migration, and invasion of osteosarcoma cells. Mechanistically, THZ1 treatment suppresses a large group of super enhancer containing MYC target genes including CDK6 and TGFB2. These findings revealed that the MYC-driven super enhancer signaling is crucial for the osteosarcoma tumorigenesis and targeting the MYC/super enhancer axis represents as a promising therapeutic strategy for treatment of osteosarcoma patients.
TableS2 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma

Tingting Liu,Juan Wang,Hongbo Yang,Qiushi Jin,Xiaotao Wang,Yihao Fu,Yu Luan,Qixuan Wang,Mark W. Youngblood,Xinyan Lu,Lucia Casadei,Raphael E. Pollock,Feng Yue

DOI: https://doi.org/10.1158/0008-5472.22730672.v1

2023-01-01

Abstract:H3K27Ac ChIP-seq Patient Sample Statistics
Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Yongheng Chen,Ying,Wenlong Ma,Hongchao Ma,Liang Shi,Xuefeng Gao,Min Jia,Meiqi Li,Xiaoman Song,Weixiao Kong,Wei Chen,Xiangyi Zheng,Tobias Achu Muluh,Xiaobin Wang,Maolin Wang,Xing-sheng Shu

DOI: https://doi.org/10.1158/0008-5472.25603759

2024-01-01

Abstract:Target sequences of shRNAs and sgRNAs used in this study.
Supplementary File 1 from Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Junyu Yang,Chong Gao,Miao Liu,Yao-Chung Liu,Junsu Kwon,Jun Qi,Xi Tian,Alicia Stein,Yanjing V. Liu,Nikki R. Kong,Yue Wu,Shenyi Yin,Jianzhong Xi,Zhiyuan Chen,Kalpana Kumari,Hannan Wong,Hongbo Luo,Leslie E. Silberstein,Julie A.I. Thoms,Ashwin Unnikrishnan,John E. Pimanda,Daniel G. Tenen,Li Chai

DOI: https://doi.org/10.1158/0008-5472.22430467

2023-01-01

Abstract:List of primers used in the paper
Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Qing Cao,Zhengshuai Song,Hailong Ruan,Cheng Wang,Yan Xiong,Bingcheng Lin,Keshan Wang,Gong Chen,Tianbo Xu,Wen Xu,Xiong Zhang,Di Liu,Ming–Hsuan Yang,Diwei Zhou,Hongmei Yang,Ke Chen,Xiaoping Zhang

DOI: https://doi.org/10.1158/1078-0432.22473300.v1

2023-01-01

Abstract:Primers used in quantitative polymerase chain reaction for analysis of genomic amplification
CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma

Tao Zhang,Jingjie Li,Mengkai Yang,Xinglong Ma,Zhuoying Wang,Xiaojun Ma,Mengxiong Sun,Wei Sun,Jing Xu,Yingqi Hua,Zhengdong Cai

DOI: https://doi.org/10.1038/s41388-022-02446-z

IF: 8.756

2022-08-30

Oncogene

Abstract:Osteosarcoma derives from primitive bone-forming mesenchymal cells and is the most common primary bone malignancy. Therapeutic targeting of osteosarcoma has been unsuccessful; therefore, identifying novel osteosarcoma pathogenesis could offer new therapeutic options. CDK7 is a subunit within the general transcription factor TFIIH. We aim to explore the new mechanism by which CDK7 regulates osteosarcoma and our studies may provide new theoretical support for the use of CDK7 inhibitors in the treatment of osteosarcoma. Here, we investigate the molecular mechanism underlying the association between CDK7 and GRP78 in osteosarcoma. Specifically, we find that an E3 ubiquitin ligase TRIM21 binds and targets GRP78 for ubiquitination and degradation, whereas CDK7 phosphorylates GRP78 at T69 to inhibit TRIM21 recruitment, leading to GRP78 stabilization. Notably, a CDK7-specific inhibitor, THZ1, blunts osteosarcoma growth and metastasis. Combination treatment with CDK7 and GRP78 inhibitors yield additive effects on osteosarcoma growth and progression inhibition. Thus, simultaneous suppression of CDK7 and GRP78 activity represents a potential new approach for the treatment of osteosarcoma. In conclusion, the discovery of this previously unknown CDK7/GRP78 signaling axis provides the molecular basis and the rationale to target human osteosarcoma.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
TableS5 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma

Tingting Liu,Juan Wang,Hongbo Yang,Qiushi Jin,Xiaotao Wang,Yihao Fu,Yu Luan,Qixuan Wang,Mark W. Youngblood,Xinyan Lu,Lucia Casadei,Raphael E. Pollock,Feng Yue

DOI: https://doi.org/10.1158/0008-5472.22730663.v1

2023-01-01

Abstract:Sequence Data Information in Lipo863B
TableS4 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma

Tingting Liu,Juan Wang,Hongbo Yang,Qiushi Jin,Xiaotao Wang,Yihao Fu,Yu Luan,Qixuan Wang,Mark W. Youngblood,Xinyan Lu,Lucia Casadei,Raphael Pollock,Feng Yue

DOI: https://doi.org/10.1158/0008-5472.22730666.v1

2023-01-01

Abstract:Patient Sample WGS data statistics
Discovery of 2-Amino-3-cyanothiophene Derivatives As Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis.

Wangrui Jin,Tao Zhang,Wenbo Zhou,Peng He,Yue Sun,Shijia Hu,Huang Chen,Xinglong Ma,Yangrui Peng,Zhengfang Yi,Mingyao Liu,Yihua Chen

DOI: https://doi.org/10.1021/acs.jmedchem.2c00004

IF: 8.039

2022-01-01

Journal of Medicinal Chemistry

Abstract:Osteosarcoma is one of the most common malignant bone tumors. However, the treatment and clinical outcomes of osteosarcoma have hardly changed over the past three decades due to the comprehensive heterogeneity and higher rate of mutation of osteosarcoma. Recent studies have shown that STAT3 has the potential to suppress the proliferation and metastasis of osteosarcoma. In this study, a novel class of 2-amino-3-cyanothiophene derivatives were designed and synthesized to inhibit osteosarcoma by targeting STAT3. Representative compound 6f showed potent antiproliferative effects against osteosarcoma cells, directly bound to the STAT3 SH2 domain with a KD of 0.46 μM, and inhibited the phosphorylation of STAT3 Y705 in a dose-dependent manner. Furthermore, compound 6f promoted osteosarcoma cell apoptosis in vitro and significantly suppressed the growth and metastasis of osteosarcoma in vivo. These findings demonstrate that targeting STAT3 may be a feasible therapeutic strategy for the treatment of metastatic osteosarcoma.
Table S1 from Targeting the Mtor Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity

Yiyu Dong,Yongxing Gong,Fengshen Kuo,Vladimir Makarov,Ed Reznik,Gouri J. Nanjangud,Ömer Aras,Haisen Zhao,Rui Qu,James A. Fagin,Eric Sherman,Bin Xu,Ronald Ghossein,Timothy A. Chan,Ian Ganly

DOI: https://doi.org/10.1158/1535-7163.22522545.v1

2023-01-01

Abstract:Quantitative RT-PCR primer sequences
Construction of a 5-Gene super-enhancer-related signature for osteosarcoma prognosis and the regulatory role of TNFRSF11B in osteosarcoma

Jun Liu,Chengfeng Yi,Deliang Gong,Qingzhong Zhao,Han Xie,Shibing Zhao,Hang Yu,Jianwei Lv,Erbao Bian,Dasheng Tian

DOI: https://doi.org/10.1016/j.tranon.2024.102047

Abstract:Osteosarcoma, one of the most common primary malignancies in children and adolescents, has the primary characteristics of a poor prognosis and high rate of metastasis. This study used super-enhancer-related genes derived from two different cell lines to construct five novel super-enhancer-related gene prognostic models for patients with osteosarcoma. The training and testing datasets were used to confirm the prognostic models of the five super-enhancer-related genes, which resulted in an impartial predictive element for osteosarcoma. The immunotherapy and prediction of the response to anticancer drugs have shown that the risk signature of the five super-enhancer-related genes positively correlate with chemosensitivity. Furthermore, functional analysis of the risk signature genes revealed a significant relationship between gene groups and the malignant characteristics of tumours. TNF Receptor Superfamily Member 11b (TNFRSF11B) was selected for functional verification. Silencing of TNFRSF11B suppressed the proliferation, migration, and invasion of osteosarcoma cells in vitro and suppressed osteosarcoma growth in vivo. Moreover, transcriptome sequencing was performed on MG-63 cells to study the regulatory mechanism of TNFRSF11B in osteosarcoma cells, and it was discovered that TNFRSF11B is involved in the development of osteosarcoma via the phosphoinositide 3-kinase signalling pathway. Following the identification of TNFRSF11B as a key gene, we selected an inhibitor that specifically targeted this gene and performed molecular docking simulations. In addition, risedronic acid inhibited osteosarcoma growth at both cellular and molecular levels. In conclusion, the super-enhancer-related gene signature is a viable therapeutic tool for osteosarcoma prognosis and treatment.
Correction: CDKL3 Promotes Osteosarcoma Progression by Activating Akt/PKB

Aina He,Lanjing Ma,Yujing Huang,Haijiao Zhang,W. Duan,Zexu Li,Teng Fei,J. Yuan,Hao Wu,Liguo Liu,Yueqing Bai,Wentao Dai,Yonggang Wang,Hongtao Li,Yong Sun,Yaling Wang,Chunyan Wang,Ting Yuan,Qing-cheng Yang,Songhai Tian,Min Dong,Ren Sheng,Dongxi Xiang

DOI: https://doi.org/10.26508/lsa.202201656

IF: 5.781

2022-01-01

Life Science Alliance

Abstract:This study demonstrates that CDKL3 regulates Akt activation and its downstream targets to promote OS progression, creating a therapeutically targetable vulnerability in treatment of OS.
Targeting the Anaphase-Promoting Complex/cyclosome (APC/C)- Bromodomain Containing 7 (BRD7) Pathway for Human Osteosarcoma

Kaishun Hu,Dan Liao,Wenjing Wu,An-Jia Han,Hui-Juan Shi,Fen Wang,Xin Wang,Li Zhong,Tingmei Duan,Yuanzhong Wu,Jingying Cao,Jianjun Tang,Yi Sang,Li Wang,Xiaobin Lv,Shuangbing Xu,Ru-Hua Zhang,Wu-Guo Deng,Sheng-Ping Li,Yi-Xin Zeng,Tiebang Kang

DOI: https://doi.org/10.18632/oncotarget.1816

2014-01-01

Oncotarget

Abstract:Osteosarcoma is the most common primary malignant bone tumor in childhood and adolescence and has a propensity for local invasion and early lung metastasis. However, the current therapies often result in chemoresistance, and a therapeutic target is not available in the clinic for osteosarcoma. Here, we report that BRD7 forms a complex with the anaphase-promoting complex/cyclosome (APC/C) and is degraded by APC/Ccdh1 and APC/Ccdc20 during the cell cycle. Moreover, BRD7 is a tumor suppressor in osteosarcoma, and the BRD7 mutant resistant to degradation by APC/C is more efficient than the wild-type protein at suppressing proliferation, colony formation, and tumor growth of osteosarcoma in vitro and in vivo. The combination of proTAME, an inhibitor of APC/C, with chemotherapeutic drugs efficiently targets osteosarcoma in vitro. Furthermore, there is a strong inverse correlation of protein levels between BRD7 and Cdh1 or Cdc20, and lower BRD7 expression is an indicator for poor prognosis in patients with osteosarcoma. Collectively, our results indicate that targeting the APC/C-BRD7 pathway may be a novel strategy for treating osteosarcoma.
Supplementary Table S4 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Yuqin Song,Zhengming Jin,Zhi-Ming Li,Yanyan Liu,Lanfang Li,Chuan He,Hang Su,Hui Zhou,Kunyan Li,Siguo Hao,Xuelan Zuo,Jianyuan Wu,Dengju Li,Meng Wu,Xiuhua Sun,Junyuan Qi,Zhen Cai,Zengjun Li,Yijing Li,Yanhua Huang,Jie Shen,Zhenyu Xiao,Jun Zhu

DOI: https://doi.org/10.1158/1078-0432.25515642.v1

2024-01-01

Abstract:<p>Supplementary Table S4. Anti-tumor activity in efficacy evaluable set.</p>
Identification of DDX5 as a Potential Therapeutic Target of Osteosarcoma Using Thiazolone Probes

Donghui Sun,Li Kang,Xuwen Chen,Jian Xue,Xin Wu,Jiemin Wong,Qinghua Wei,Shunying Liu

DOI: https://doi.org/10.1021/acschembio.4c00360

IF: 4.634

2024-07-29

ACS Chemical Biology

Abstract:Osteosarcoma (OS) is a rare malignant tumor that has predominantly affected children and adolescents in the past 50 years. The genomes of OS tumors exhibit a high degree of complexity, which leads to the great challenge of target identification for anti-OS. To date, no efficient therapeutic target for the treatment of OS has been validated in clinical practice. In our previous drug hunting for the treatment of OS by phenotypic screening, we found that thiazolone derivate (R)-8i was an effective...

biochemistry & molecular biology

Table S3 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

Table S1 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Table S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma

TableS2 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma

Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Supplementary File 1 from Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Supplementary Table S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma

TableS5 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma

TableS4 from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma

Discovery of 2-Amino-3-cyanothiophene Derivatives As Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis.

Table S1 from Targeting the Mtor Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity

Construction of a 5-Gene super-enhancer-related signature for osteosarcoma prognosis and the regulatory role of TNFRSF11B in osteosarcoma

Correction: CDKL3 Promotes Osteosarcoma Progression by Activating Akt/PKB

Targeting the Anaphase-Promoting Complex/cyclosome (APC/C)- Bromodomain Containing 7 (BRD7) Pathway for Human Osteosarcoma

Supplementary Table S4 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Identification of DDX5 as a Potential Therapeutic Target of Osteosarcoma Using Thiazolone Probes